| 000 | 01816 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518061809.0 | ||
| 264 | 0 | _c20200403 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1776-260X | ||
| 024 | 7 |
_a10.1007/s11523-019-00667-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiewen, Heike | |
| 245 | 0 | 0 |
_aTherapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX). _h[electronic resource] |
| 260 |
_bTargeted oncology _c10 2019 |
||
| 300 |
_a577-590 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xtherapeutic use |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aGenetic Engineering |
| 650 | 0 | 4 | _aHCT116 Cells |
| 650 | 0 | 4 | _aHeterografts |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aMembrane Proteins _xgenetics |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 700 | 1 | _aMarkuly, Norbert | |
| 700 | 1 | _aLäubli, Heinz | |
| 700 | 1 | _aLiu, Yang | |
| 700 | 1 | _aMatter, Matthias S | |
| 700 | 1 | _aLiewen, Nora | |
| 700 | 1 | _aRenner, Christoph | |
| 700 | 1 | _aZippelius, Alfred | |
| 700 | 1 | _aStenner, Frank | |
| 773 | 0 |
_tTargeted oncology _gvol. 14 _gno. 5 _gp. 577-590 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11523-019-00667-z _zAvailable from publisher's website |
| 999 |
_c30131824 _d30131824 |
||